Expanded FDA OTC inspection authority will ease global marketing -- FDAer.
This article was originally published in The Tan Sheet
Executive Summary
LABEL PRINTING ERROR REDUCTION THROUGH GMPs should be priority for FDA and OTC drug manufacturers, FDA New Jersey District Director Douglas Ellsworth recommended at the Nonprescription Drug Manufacturers Association's annual small business seminar in East Rutherford, N.J. March 11-12. Noting that FDA has worked with industry for "a number of years" to reduce the amount of recalls related to mislabeling problems, such as the wrong label being attached to bottles, the FDAer said "we need to focus some of our efforts on the printing aspect -- what controls are necessary" to avoid misprints.